Dentsply Sirona has announced that board member Daniel Scavilla will officially take over as president and CEO of the company on August 1, 2025, replacing Simon Campion, who will leave on July 31, 2025.
Scavilla has more than 30 years of experience in the medical technology and pharmaceutical industries. Just months after joining the Dentsply Sirona board, he served as president and CEO of Globus Medical, where he led the $3 billion all-stock acquisition of NuVasive and successfully drove the company’s integration.
Prior to that, he spent nearly 30 years at Johnson & Johnson in a variety of senior financial and operational positions. Scavilla holds a bachelor’s degree in finance and organizational behavior from La Salle University and a master’s degree in international management from Temple University.
Gregory T. Lucier, Chairman of the Board, said: “Dan’s appointment reflects the Board’s commitment to enhancing shareholder value and driving the company’s future development.
His extensive executive experience and focus on business growth, product innovation and operational financial excellence make him the ideal leader to lead Dentsply Sirona into the next chapter.
We believe that the dental market has great potential and Dan will help accelerate the company’s transformation, reshape its industry leadership and realize long-term value.”
Scavilla is looking forward to his new role: “I have always highly recognized the brand value of Dentsply Sirona. Since joining the Board, I have a deeper understanding of the company’s potential. Although the transformation has been effective, we still have room for improvement.
I look forward to working with the team to drive continued growth in business and financial performance and create greater value for stakeholders.”
Lucier also thanked Campion, who is outgoing, for his contribution to the company, saying that he has laid a solid foundation for Dentsply Sirona and wished him the best in the future. Campion also expressed his gratitude for his leadership over the past three years and is full of confidence in the company’s future development.
As part of the transition arrangements, Campion has resigned from the board of directors and Scavilla will continue to serve on the board but will no longer serve on the audit and finance committees.
